Position in SVTRnew
Snapshot 2026-10-31- Startup SignalsRankedof 2,232
- Life SciencesRankedof 237
- AI for ScienceRankedof 112
- Drug DiscoveryRankedof 65
About
Allox is a Barcelona techbio spun out of the Centre for Genomic Regulation (CRG) in 2023, combining deep mutational scanning, high-throughput phenotyping and AI-driven biophysical modelling to map allosteric sites and develop small molecules against hard-to-drug targets; lead candidate ALX-001 is preclinical.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Company· 3
Investor· 3
Founders / team· 4
Funding history
- 2026-10-29Seed$11M
Investors · Asabys Partners, CDTI, Institut Català de FinancesSource · european-biotechnology.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Allox
Allox is a Barcelona techbio spun out of the Centre for Genomic Regulation (CRG) in 2023, combining deep mutational scanning, high-throughput phenotyping and AI-driven biophysical modelling to map allosteric sites and develop small molecules against hard-to-drug targets; lead candidate ALX-001 is preclinical.
Seed · 2026-10
—
United States
BusinessLatest roundTotal raisedDate- Kekulai
Automates end-to-end small-molecule drug discovery with AI agent platform Allchymie, focusing on lead compound screening for "undruggable" autoimmune/inflammatory targets.
— - Leash Biosciences
Uses AI and machine learning to predict small-molecule drug candidates for any protein
Seed · $9M · 2024-04
$9M - PsiThera
Oral small-molecule drugs for immune and inflammatory diseases, using AI to model protein "kinetics" (QUAISAR™ platform)
Series A · $48M · 2025-12
$48M
China
BusinessLatest roundTotal raisedDate- Nutshell Therapeutics
AI and physics-based computation for allosteric small-molecule drug discovery against hard-to-drug targets such as transcription factors
Series C · 2026-09
— - MindRank
Designs and develops novel small-molecule drugs using its in-house AI drug discovery platform MAP
Series B · $52M · 2026-07
$52M - NeuShen Therapeutics
Novel drugs for CNS psychiatric and neurological disorders, with the NeuChime small-molecule discovery platform and NeuGem AAV gene therapy platform; lead programs include NS-136 (M4 positive allosteric modulator) and NS-041 (KCNQ2/3 activator)
Series B · 2026-09
—
Europe
BusinessLatest roundTotal raisedDate- Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies
Series B · $2.7B · 2026-05
$2.7B - Sightera Biosciences
AI-native drug discovery: patient-derived disease models and generative AI to design small-molecule cancer/fibrosis therapies
Pre-Seed · $3M · 2026-07
$3M - Undecimal Bio
AI-driven discovery of conjugate molecules for extrahepatic targeted delivery of RNA drugs (DELiveri platform)
Seed · 2026-10
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Y Combinator
40 Life Sciences deals in the last 24 months · 28 at a nearby stage · 3 in Western Europe
Request intro →General Catalyst
40 Life Sciences deals in the last 24 months · 19 at a nearby stage · 1 in Western Europe
Request intro →Alumni Ventures
12 Life Sciences deals in the last 24 months · 8 at a nearby stage · 1 in Western Europe
Request intro →Accel
12 Life Sciences deals in the last 24 months · 8 at a nearby stage · 3 in Western Europe
Request intro →LifeX Ventures
8 Life Sciences deals in the last 24 months · 5 at a nearby stage · 1 in Western Europe
Request intro →Index Ventures
8 Life Sciences deals in the last 24 months · 4 at a nearby stage · 3 in Western Europe
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.